Other versions:

(Verbatim name)

ID

(Catalog Number)

ORG

DES

Invalid DOI was provided, please try again

XML
PDF
 
 
Bluesky
Twitter
Facebook
Telegram
Mendeley
Reddit
Notify a colleague
  • ContentsContents
  • Article InfoArticle Info
  • CiteCite
  • MetricsMetrics
  • CommentComment
  • RelatedRelated
  • FigsFigs
  • TabsTabs
  • TaxaTaxa
  • RefsRefs
  • CitedCited
  • Article title
  • Abstract
  • Keywords
  • Introduction
  • Materials and methods
    • Inclusion criteria
    • Exclusion criteria
  • Results
    • Significance of HER2 in breast and gastric cancer
    • HER2-targeted therapies
      • Trastuzumab
      • Pertuzumab
      • Ado-trastuzumab emtansine (T-DM1)
      • Lapatinib
    • Clinical trials and evidence
    • Resistance mechanisms
      • Primary resistance
      • Acquired resistance
    • Combination therapies
      • Dual HER2 blockade
      • HER2-targeted therapy with chemotherapy
    • Biomarkers for HER2-targeted therapy
    • Adverse effects and management
      • Cardiotoxicity
      • Pulmonary toxicity
      • Comprehensive safety profile considerations
    • Future directions
  • Immune checkpoint inhibitors in HER2-positive cancers
  • Conclusion
  • Acknowledgments
  • Additional information
  • References
Subscribe to email alerts for current Article's categories
Powered by